Treating M

Treating Mild Chronic Hypertension in Pregnancy Associated With Better Outcomes

In pregnant women with mild chronic hypertension, a strategy of targeting blood pressure to <140/90 mm Hg was associated with better pregnancy outcomes compared with a strategy of reserving treatment only for women with severe hypertension, with no increase in the risk of small-for-gestational-age birth weight, according to a study published in The New England Journal of Medicine. “Chronic hypertension causes serious and life-threatening complications for pregnant women and their babies,” said Alan Tita, MD, Marnix E. Heersink School of Medicine, University of Alabama at Birmingham, Birming...

Study highlights possible ongoing microvascular/endothelial dysfunction in pathogenesis of post...

Findings from a study published in Blood Advances suggest possible ongoing microvascular/endothelial...

Virtual Cardiac Rehabilitation Produces Similar Results as In-Person Treatment

Virtual and hybrid cardiac rehabilitation services produced similar improvements in patient function...


Suggested videos

Search:
Date
Filters:
Atrial fib
19:010

Atrial fibrillation guidelines into clinical practice

Presenter: Daniel Scherr
Cardiology
EHRA 2022
Recent dev
7:02

Recent developments of the conduction system pacing

Presenter: Hung-Fat Tse
Cardiology
EHRA 2022
Conduction
7:07

Conduction system pacing: ready for prime time?

Presenter: Mauro Biffi
Cardiology
EHRA 2022
What do ne
7:17

What do new guidelines tell us about conduction system pacing?

Presenter: Michael Glikson
Cardiology
EHRA 2022
Antithromb
5:33

Antithrombotic Approaches to Reduce the Risk of Secondary Event in CAD and PAD

Presenter: Marc P. Bonaca
Cardiology
ACC 2022
Results fr
9:16

Results from the EMPULSE Trial

Presenter: Mikhail Kosiborod
Cardiology
ACC 2022
Effect of
3:03

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk - The SCORED Trial

Presenter: Deepak Bhatt
Cardiology
ACC 2022
Protecting
9:16

Protecting comorbid patients with atrial fibrillation from stroke

Presenter: John Camm
Cardiology
EHRA 2022
Bentracima
3:16

Bentracimab Immediately and Significantly Reverses the Antiplatelet Effects of Ticagrelor in Older People

Presenter: Deepak Bhatt
Cardiology
ACC 2022
EHRA scien
11:56

EHRA scientific documents 2022

Presenter: Cecilia Linde
Cardiology
EHRA 2022
Guidance i
6:01

Guidance in Heart Failure Care at ACC 2022

Presenter: David E. Lanfear
Cardiology
ACC 2022
How to red
5:41

How to reduce limb events including amputations in our patients?

Presenter: Manesh Patel
Cardiology
ACC 2022
Updated Cu
8:24

Updated Cumulative Results of Treatment With Mavacamten From the EXPLORER-LTE Cohort of the MAVA-LTE Study

Presenter: Florian Rader
Cardiology
ACC 2022
Highlights
10:33

Highlights of the San Antonio Breast Cancer Symposium 2021

Presenter: Virginia G. Kaklamani
Oncology : Breast Cancer
SABCS 2021
Novelties
8:35

Novelties in the treatment of myelofibrosis and polycythemia vera 2021

Presenter: Srdan Verstovsek
Hematology
ASH 2021
Risks for
5:01

Risks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology

Presenter: Lisa K. Hicks
Hematology
ASH 2021
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
Paradigm s
12:05

Paradigm shift in the early NSCLC? The role of ICIs in the adjuvant treatment

Presenter: Federico Cappuzzo
Oncology
How will t
9:43

How will the current therapeutic options change the treatment of RCC in the daily practice?

Presenter: Camillo Porta
Oncology
The role o
5:58

The role of immune checkpoint inhibitors and VEGF TKIs in the adjuvant treatment of renal cell carcinoma

Presenter: David F. McDermott
Oncology
Treatment
11:50

Treatment intensification in the treatment of prostate cancer

Presenter: Oliver Sartor
Oncology
Pembrolizu
16:35

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma

Presenter: Stefan N. Symeonides
Oncology
State of t
6:13

State of the art treatment of bladder cancer

Presenter: Matthew R. Zibelman
Oncology
First-line
7:41

First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer

Presenter: Ken Kato
Oncology
Treatment
3:27

Treatment of iron deficiency in acute and chronic heart failure

Presenter: Piotr Ponikowski
Cardiology
Alcohol se
6:32

Alcohol septal ablation in hypertrophic cardiomyopathy: past and future

Presenter: Hubert Seggewiss
Cardiology
The use of
3:35

The use of SGLT2 inhibitors in the prevention and treatment of heart failure

Presenter: Petar M. Seferovic
Cardiology
Direct myo
5:15

Direct myosin inhibitors in hypertrophic cardiomyopathy: a new era?

Presenter: Iacopo Olivotto
Cardiology
Diagnostic
10:55

Diagnostic delay in pulmonary arterial hypertension

Presenter: Barbro Kjellström and Bodil Ivarsson
Clinical I
6:21

Clinical Impact of Liraglutide as a Treatment of Obesity

Presenter: Babak Dehestani
Internal Medicine
Associatio
20:17

Association of GLP 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events

Presenter: Michael Camilleri
Internal Medicine
Liraglutid
13:26

Liraglutide for Weight Management in the Real World

Presenter: Roman Vangoitsenhoven
Cardiology , Diabetology
The role o
10:22

The role of GLP-1 receptor agonists in weight reduction and cardiovascular risk reduction

Presenter: Michael A. Nauck
Cardiology , Diabetology